Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise

Name: Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
Uploaded: 2025-12-04T05:00:00+00:00
Description: This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post

Home
SERIES
DermWire TV

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

DWTV Extra: Psoriasis Advocacy
DWTV Extra: Psoriasis Advocacy
DermWire TV
DWTV Extra: Psoriasis Advocacy
- Frida Dunger
Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
DermWire TV
Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
Increased APS Risk for Psoriasis Patients, Plus More
Increased APS Risk for Psoriasis Patients, Plus More
DermWire TV
Increased APS Risk for Psoriasis Patients, Plus More
DWTV Extra: Vitiligo Ingenuity Award
DWTV Extra: Vitiligo Ingenuity Award
DermWire TV
DWTV Extra: Vitiligo Ingenuity Award

Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise

Recommended

Title

Share on ReachMD

Get a Dose of PracticalDermatology in Your Inbox and Practice Smarter Medicine